Skip to main content
. 2024 Apr 27;7:41. doi: 10.1186/s42155-024-00452-8

Table 1.

ASVS baseline characteristics

Characteristic Number of subjects at Baseline (n = 100) Number of subjects at 12 m (n = 90) Number of subjects at 36 m (n = 70)
Gender
 Male 41 37 (41.1) 30 (42.9)
 Female 59 53 (58.9) 40 (57.1)
Mean age, years (SD) 60.1 ± 12.8 60.7 ± 12.8 60.9 ± 13.6
Mean BMI, kg/m2 (SD) 26.7 ± 4.58 26.6 ± 4.65 26.2 ± 4.32
Ethnic Group
 Chinese 71 64 (71.1) 51 (72.9)
 Malay 11 9 (10.0) 8 (11.4)
 Indian 16 16 (17.8) 10 (14.3)
 Others 2 1 (1.1) 1 (1.43)
Smoking
 Smoker 9 6 (6.7) 4 (5.71)
 Non-Smoker 84 78 (86.7) 63 (90.0)
 Former Smoker 7 6 (6.7) 3 (4.29)
Primary Symptoms
 Pain 37 32 (35.6) 24 (34.3)
 Aching 43 33 (36.7) 25 (35.7)
 Swelling 57 52 (57.8) 39 (55.7)
 Heaviness 46 45 (50.0) 29 (41.4)
 Burning 2 1 (1.1) 0 (0.00)
 Itch 26 24 (26.7) 14 (20.0)
 Others 30 4 (4.4) 22 (31.4)
Comorbidities
 Hypertension 45 40 (44.4) 31 (44.3)
 Hyperlipidemia 37 33 (36.7) 24 (34.3)
 Diabetes Mellitus 16 14 (15.6) 11 (15.7)
 Ischemic Heart Disease 6 5 (5.6) 4 (5.71)
CEAP category
 C2 (varicose veins) 24 20 (22.2) 15 (21.4)
 C3 (edema) 33 30 (33.3) 25 (35.7)
 C4a (pigmentation/eczema) 32 28 (31.1) 21 (30.0)
 C4b (lipodermatosclerosis) 4 4 (4.4) 3 (4.29)
 C5 (healed venous ulcer) 7 7 (7.8) 3 (4.29)
Duration of Varicose Veins (months), median (IQR) 24.00 (7.75–60.0) 24.00 (7.00–60.0) 24.0 (6.00 – 60.0)
Distribution of Truncal Endovenous Ablation (n = 151 legs) (n = 138 legs) (n = 107 legs)
 GSV 49 (32.5%) 41 (29.7%) 35 (32.7)
 Bilateral GSV 96 (63.6%) 92 (66.7%) 68 (63.6)
 SSV 1 (0.7%) 1 (0.7%) 1 (0.93)
 Combined unilateral GSV and SSV or ATV 5 (3.3%) 4 (2.9%) 3 (2.80)
Total number of truncal veins treated (n = 156 veins) (n = 142 veins) (n = 110veins)
 GSV 150 (96.2) 137 (96.5) 106 (96.4)
 SSV 5 (3.2) 4 (2.82) 4 (3.64)
 ATV 1 (0.6) 1 (0.7) 0 (0.0)